Stocks With the Highest and Lowest Liquidity - Goldman Sachs
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Novocure(NVCR.US) Director Sells US$23,032.85 in Common Stock
$Novocure(NVCR.US)$ Director VERNON W ANTHONY sold 964 shares of common stock on Jun 4, 2024 at an average price of $23.893 for a total value of $23,032.85.Source: Announcement What is statement of ch
Novocure(NVCR.US) Director Sells US$23,025.24 in Common Stock
$Novocure(NVCR.US)$ Director LEUNG GABRIEL sold 964 shares of common stock on Jun 4, 2024 at an average price of $23.8851 for a total value of $23,025.24.Source: Announcement What is statement of chan
Novocure(NVCR.US) Director Sells US$23,027.45 in Common Stock
$Novocure(NVCR.US)$ Director Scannell Timothy J sold 964 shares of common stock on Jun 4, 2024 at an average price of $23.8874 for a total value of $23,027.45.Source: Announcement What is statement of
A Closer Look at 7 Analyst Recommendations For NovoCure
7 analysts have shared their evaluations of NovoCure (NASDAQ:NVCR) during the recent three months, expressing a mix of bullish and bearish perspectives.The table below summarizes their recent ratings,
Novocure Price Target Maintained With a $22.00/Share by HC Wainwright & Co.
Novocure Price Target Maintained With a $22.00/Share by HC Wainwright & Co.
NovoCure Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/04/2024 -8.41% HC Wainwright & Co. $22 → $22 Reiterates Neutral → Neutral 05/02/2024 -8.41% HC Wainwrig
Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating
NovoCure (NVCR) has an average rating of outperform and price targets ranging from $14.50 to $42, according to analysts polled by Capital IQ. Price: 24.01, Change: +0.12, Percent Change: +0.50
Express News | Novocure Ltd : Wedbush Raises Target Price to $24 From $21
Novocure Tumor Treating Fields Decreases Progression of Brain Metastases
Express News | NovoCure Shares Are Trading Higher After the Company Announced That the Phase 3 METIS Trial Met Its Primary Endpoint
Express News | Novocure Reports Presentation Of Clinical Data From Phase 3 METIS Trial; Says Trial Met Its Primary Endpoint, Demonstrating Statistically Significant Improvement In Time To Intracranial Progression
Express News | Novocure Ltd: Preliminary Analyses of Key Secondary Endpoints Did Not Demonstrate Statistical Significance
Express News | Metis Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression With Improved Quality of Life Deterioration-Free Survival
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression With Improved Quality of Life Deterioration-Free Survival
Novocure (NASDAQ: NVCR) today announced the presentation of clinical data from the phase 3 METIS trial, which investigated the use of Tumor Treating Fields (TTFields) therapy in the treatment of brain metastases from non-small cell lung cancer (NSCLC).
Express News | Novocure Ltd : JP Morgan Raises Target Price to $20 From $17
Piper Sandler Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $28
Piper Sandler analyst Jason Bednar maintains $Novocure(NVCR.US)$ with a buy rating, and maintains the target price at $28.According to TipRanks data, the analyst has a success rate of 36.6% and a tota
Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Arrowhead Pharmaceuticals (ARWR) and NovoCure (NVCR)
Express News | Novocure Ltd - Outcomes Observed in Tiger Study Are Consistent With Survival and Safety Results From Novocure's Phase 3 Ef-14 Clinical Trial
No Data